Roy J. and Lucille A. Carver College of Medicine

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

Retrieved on: 
Wednesday, June 21, 2023
ENDO, Roy J. and Lucille A. Carver College of Medicine, Senior, Serum, Pediatric endocrinology, SDS, DRS, MD, Division, Update, Transgender hormone therapy, LUMO, Database, University, Mother, University of Iowa Hospitals and Clinics, Albany Medical Center, Lumos, Growth, Hospital, NIH, Abstract, Endocrinology, Aes, University of Chile, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Șaeș, Public key certificate, Endocrine Society, Research, KOL, Saint Andrew's Society, University of Iowa, Oral, Diabetes, AHV, Pharmaceutical industry, Nursing, Dietary supplement, Child, Pediatrics

AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, is hosting today a virtual Key Opinion Leader (KOL) Webinar where Drs. Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting, held in Chicago, Illinois, June 15-18, 2023.

Key Points: 
  • Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting, held in Chicago, Illinois, June 15-18, 2023.
  • Cassorla and Tansey will be available to answer questions following their formal presentations.
  • To register for the virtual KOL Event, please click through the link HERE .
  • Cassorla and Tansey gave two oral presentations in the Update on Growth Disorders session at the 2023 ENDO Meeting.

Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

Retrieved on: 
Thursday, May 25, 2023
ENDO, Roy J. and Lucille A. Carver College of Medicine, Senior, Pediatric endocrinology, DRS, MD, Division, Transgender hormone therapy, LUMO, University, Mother, University of Iowa Hospitals and Clinics, Albany Medical Center, Growth, Hospital, NIH, Abstract, Endocrinology, University of Chile, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Public key certificate, Endocrine Society, Research, KOL, University of Iowa, Oral, Diabetes, Pharmaceutical industry, Nursing, Child, Pediatrics

Lumos Pharma will host a virtual Key Opinion Leader (KOL) Webinar on June 21, 2023, 11:00 AM – 12 PM EDT where Drs.

Key Points: 
  • Lumos Pharma will host a virtual Key Opinion Leader (KOL) Webinar on June 21, 2023, 11:00 AM – 12 PM EDT where Drs.
  • Fernando Cassorla and Michael Tansey will review interim data evaluating oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the ENDO Meeting.
  • is currently Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research of the University of Chile, a position he has held since 1993.
  • Dr. Tansey also currently serves as Clinical Director for Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Iowa.

Vytalize Health Names Derek Kang Chief Compliance Officer

Retrieved on: 
Wednesday, February 15, 2023
Health, Roy J. and Lucille A. Carver College of Medicine, Hospital, Bachelor of Science in Nursing, Safety, University of Wisconsin–Madison, University, Patient, Allina Health, Research, UCLA Health, Privacy, Master, Growth, Texas Children's Hospital, Grinnell College, Management, Nursing, Science

HOBOKEN, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Vytalize Health , a leading risk-bearing provider-enablement platform, announced that Derek Kang has joined its executive team as Chief Compliance Officer.

Key Points: 
  • HOBOKEN, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Vytalize Health , a leading risk-bearing provider-enablement platform, announced that Derek Kang has joined its executive team as Chief Compliance Officer.
  • We are thrilled to welcome a leader of Derek's caliber and integrity to the Vytalize team," said Faris Ghawi, CEO and Co-Founder of Vytalize.
  • Kang has built successful compliance programs at some of the nation's largest and most successful healthcare organizations.
  • Previously, he served as Chief Compliance Officer at UCLA Health, overseeing clinical and teaching compliance programs, privacy and information security, physician and hospital billing, and research compliance, and led several compliance initiatives for the University of California.

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

Retrieved on: 
Tuesday, June 21, 2022
Research, Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Other Science, Science, Yan, Beverly Davidson, Partner, MBBS, University, Director, LinkedIn, Pressure, CFTR, Vertex, Inflammation, National Institute of Dental and Craniofacial Research, Therapy, Company, University College London, Tissue, AAV, Technology, CEO, University of Iowa, MRCP, Founder, Lung, Alnylam Pharmaceuticals, Board, University of Kansas, Parvoviridae, Industry, Tropism, UCL Great Ormond Street Institute of Child Health, Chairperson, FRCP, List of life sciences, Lists of diseases, Patient, Multimedia, Cystic fibrosis, Senior, CBO, Cystic Fibrosis Foundation, Gene, Research, Program, Infection, Doctor of Philosophy, UCL, Center, Roy J. and Lucille A. Carver College of Medicine, Pharmaceutical industry, Management, Pediatric nursing, Photis Kontoglou, Molecular medicine, Engelhardt, Microbiology

Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.

Key Points: 
  • Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.
  • Carbon is harnessing novel parvovirus vectors that can deliver larger gene therapy payloads with enhanced tissue specificity and with minimal neutralizing immunity.
  • Carbons technology will enable a diversified pipeline with potential applications across the wide range of tissues impacted in many unaddressed diseases.
  • Carbons scientific co-founders and scientific advisory board members are among the most experienced thought leaders in the gene therapy field.

Urology Care Foundation Announces 2022 Research Awards of Distinction

Retrieved on: 
Thursday, March 31, 2022
American Urological Association, AUA, William Carlos Williams Award, University of Pittsburgh Medical Center, Secondary research, Society, Roy J. and Lucille A. Carver College of Medicine, The Society for Basic Urologic Research, Health policy, Research, Publication, Environment, Evaluation, Pediatrics, Assistant, University of California, Los Angeles, Medical education, Scholar, FAAP, Prostate cancer, Icahn School of Medicine at Mount Sinai, Physician, Program, Foundation, Education, Creation, University, Dentistry, Management, Medicine, Pharmaceutical industry, Telehealth, Urology, Pathology, Doctor of Philosophy, Patient, MD

BALTIMORE, Md., March 31, 2022 /PRNewswire/ -- The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association, is pleased to announce the recipients of the 2022 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, Md., March 31, 2022 /PRNewswire/ -- The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association, is pleased to announce the recipients of the 2022 Research Awards of Distinction.
  • The awards acknowledge outstanding contributions to urology research, specifically in pediatrics and prostate cancer, and recognize the accomplishments of previous Urology Care Foundation awardees, the dedication of exemplary research mentors and the efforts of talented early- career scholars.
  • "We're proud to recognize this year's Urology Care Foundation Research Awardees," said Harris M. Nagler, MD, Urology Care Foundation President.
  • To learn more, visit https://www.auanet.org/research/research-funding/aua-funding/research-ho...
    About the Urology Care Foundation:The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association.

Lovelace Biomedical Presents a New Webinar on Rare Diseases and Gene Therapy Preclinical Research

Retrieved on: 
Thursday, October 21, 2021
Safety, Science, Lung, Scientist, Technical advisor, Research, Biotechnology, University, GLP, Cystic fibrosis, Pancreas, Drug development, History, Pharmacology, FDA, Degenerative disease, Infection, Center, Senior, Applied science, Toxicology, Roy J. and Lucille A. Carver College of Medicine, Lists of diseases, IND, Diabetes, Gene, Cell biology, CF, Therapy, Department, Lovelace, Medical device, Pharmaceutical industry

ALBUQUERQUE, N.M., Oct. 21, 2021 /PRNewswire/ --Lovelace Biomedical, a contract research organization, who has a vast and storied, 70 plus year history and expertise in studying respiratory diseases and developing therapeutics at the preclinical stage, will present a webinar in gene therapies for diseases, and will use Cystic Fibrosis results as a case study.

Key Points: 
  • ALBUQUERQUE, N.M., Oct. 21, 2021 /PRNewswire/ --Lovelace Biomedical, a contract research organization, who has a vast and storied, 70 plus year history and expertise in studying respiratory diseases and developing therapeutics at the preclinical stage, will present a webinar in gene therapies for diseases, and will use Cystic Fibrosis results as a case study.
  • Dr. McDonald will present on the framework for the use of rare disease models and regulatory considerations for safety.
  • Lovelace Biomedical is a contract research organization that conducts research to advance pharmaceutical and biotechnology companies in their complex drug development studies from the preclinical stage, and on to clinical trials.
  • For over 70 years, the organization has leveraged its multidisciplinary expertise in toxicology, gene therapy, neurological disorders, infectious disease, and medical countermeasures.

Richard E.B. Larew, MD, is recognized by Continental Who's Who

Retrieved on: 
Wednesday, September 8, 2021

Larew, MD, is being recognized by Continental Who's Who as a Distinguished Doctor for his four decades of exceptional work in the field of Internal Medicine.

Key Points: 
  • Larew, MD, is being recognized by Continental Who's Who as a Distinguished Doctor for his four decades of exceptional work in the field of Internal Medicine.
  • He sees patients both at Mercy Hospital, and at his office, Larew Internal Medicine, in addition to providing travel medicine consultations and services.
  • Dr. Larew received his Bachelor of Science with Honors in Botany from the University of Iowa in 1978.
  • Then, he completed an internship and a residency in Internal Medicine at the Medical College of Wisconsin in Milwaukee.

Encompass Health and University of Iowa Health System announce joint venture for rehabilitation hospital

Retrieved on: 
Tuesday, January 28, 2020
Geography of Iowa, IOWA, Health, Iowa City metropolitan area, Iowa City, Iowa, UnityPoint Health, Clinic, Hospital, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Grinnell Regional Medical Center

BIRMINGHAM, Ala. and IOWA CITY, Iowa, Jan. 28, 2020 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) and the University of Iowa Health System, the nonprofit corporation that supports the clinical, academic and research programs of University of Iowa Health Care, today announced they have entered into an agreement to jointly own a 40-bed, freestanding inpatient rehabilitation hospital currently under construction in Coralville, Iowa.

Key Points: 
  • BIRMINGHAM, Ala. and IOWA CITY, Iowa, Jan. 28, 2020 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) and the University of Iowa Health System, the nonprofit corporation that supports the clinical, academic and research programs of University of Iowa Health Care, today announced they have entered into an agreement to jointly own a 40-bed, freestanding inpatient rehabilitation hospital currently under construction in Coralville, Iowa.
  • It will be called University of Iowa Health Network Rehabilitation Hospital, a venture with Encompass Health.
  • "This joint venture will allow Encompass Health to become a part of the well-known and highly respected healthcare services already being provided by the university, which will greatly benefit our future patients."
  • Based in Iowa City, UI Health Care includes University of Iowa Hospitals & Clinics , the University of Iowa Hospitals & Clinics, the University of Iowa Roy J. and Lucille A.

The University of Iowa Carver College of Medicine Improves Student Exam Scores with Gale Interactive: Human Anatomy

Retrieved on: 
Monday, April 8, 2019
Education, Cengage, Electronic publishing, Gale, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Carver, Educational technology, Information and communications technology, IOWA

FARMINGTON HILLS, Mich. and IOWA CITY, Iowa, April 8, 2019 /PRNewswire/ --The University of Iowa Carver College of Medicine has seen improvements in student engagement and exam performance from using 3D interactive learning tools.

Key Points: 
  • FARMINGTON HILLS, Mich. and IOWA CITY, Iowa, April 8, 2019 /PRNewswire/ --The University of Iowa Carver College of Medicine has seen improvements in student engagement and exam performance from using 3D interactive learning tools.
  • The university is using Gale Interactive: Human Anatomy from Gale, a Cengage company, to conduct virtual 3D exploration.
  • Before using Gale Interactive: Human Anatomy, Hoffmann purchased an app to create videos for each of his lectures.
  • Read the entire story about the University of Iowa Carver College of Medicine success with Gale Interactive: Human Anatomy.